Last reviewed · How we verify
CHLORPROGUANIL
CHLORPROGUANIL is a chlorproguanil drug. It is currently in Phase 3 development.
Chlorproguanil works by inhibiting the enzyme dihydrofolate reductase, which is necessary for the growth and replication of malaria parasites.
Chlorproguanil is a small molecule drug in the chlorproguanil class, originally developed by an unknown entity. Its current owner is also unknown. The exact target of chlorproguanil is not specified, but it is used to treat malaria. The commercial status of chlorproguanil is unclear, with unknown patent status and generic manufacturers. Key safety considerations are not well-documented.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CHLORPROGUANIL |
|---|---|
| Drug class | chlorproguanil |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Think of it like a roadblock for the parasite's growth. Chlorproguanil blocks an enzyme that the parasite needs to make its own DNA, which is essential for it to multiply and cause illness. Without this enzyme, the parasite can't grow and multiply, allowing the body's immune system to fight it off.
Approved indications
Common side effects
Key clinical trials
- Chlorproguanil-Dapsone in Pregnant Women (PHASE1)
- IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria. (PHASE3)
- Kilimanjaro IPTi Drug Options Trial (PHASE2,PHASE3)
- Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria (PHASE3)
- A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania (PHASE3)
- Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria (PHASE2)
- Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria (PHASE3)
- Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHLORPROGUANIL CI brief — competitive landscape report
- CHLORPROGUANIL updates RSS · CI watch RSS
Frequently asked questions about CHLORPROGUANIL
What is CHLORPROGUANIL?
How does CHLORPROGUANIL work?
What drug class is CHLORPROGUANIL in?
What development phase is CHLORPROGUANIL in?
Related
- Drug class: All chlorproguanil drugs
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing